These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 25422220

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, van Laere S, Dirix L, Sweep FC, Span PN, Linn SC, Foekens JA, Sleijfer S, Berns EM, Jansen MP.
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [Abstract] [Full Text] [Related]

  • 3. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
    Harlé A, Lion M, Lozano N, Husson M, Harter V, Genin P, Merlin JL.
    Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
    [Abstract] [Full Text] [Related]

  • 4. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, Neubauer H.
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
    Zhang Y, Liu M, Yang H, Wang J, Liu H, Li X, Li J, Xu J, Li X.
    Neoplasma; 2014 Oct; 61(4):461-7. PubMed ID: 25027743
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, Zheng H.
    PLoS One; 2015 Oct; 10(3):e0120511. PubMed ID: 25816324
    [Abstract] [Full Text] [Related]

  • 11. Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
    Filipenko ML, Os'kina NA, Oskorbin IA, Mishukova OV, Ovchinnikova LK, Gershtein ES, Kushlinskii NE.
    Bull Exp Biol Med; 2017 Jun; 163(2):250-254. PubMed ID: 28726194
    [Abstract] [Full Text] [Related]

  • 12. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
    Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A.
    Clin Cancer Res; 2007 Oct 15; 13(20):6064-9. PubMed ID: 17947469
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.
    Lambert A, Salleron J, Lion M, Rouyer M, Lozano N, Leroux A, Merlin JL, Harlé A.
    Pathol Oncol Res; 2019 Jul 15; 25(3):1117-1123. PubMed ID: 30426328
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
    Oshiro C, Kagara N, Naoi Y, Shimoda M, Shimomura A, Maruyama N, Shimazu K, Kim SJ, Noguchi S.
    Breast Cancer Res Treat; 2015 Apr 15; 150(2):299-307. PubMed ID: 25736040
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of PIK3CA mutations in breast cancer subtypes.
    Arsenic R, Lehmann A, Budczies J, Koch I, Prinzler J, Kleine-Tebbe A, Schewe C, Loibl S, Dietel M, Denkert C.
    Appl Immunohistochem Mol Morphol; 2014 Jan 15; 22(1):50-6. PubMed ID: 24471188
    [Abstract] [Full Text] [Related]

  • 18. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
    Papaxoinis G, Kotoula V, Alexopoulou Z, Kalogeras KT, Zagouri F, Timotheadou E, Gogas H, Pentheroudakis G, Christodoulou C, Koutras A, Bafaloukos D, Aravantinos G, Papakostas P, Charalambous E, Papadopoulou K, Varthalitis I, Efstratiou I, Zaramboukas T, Patsea H, Scopa CD, Skondra M, Kosmidis P, Pectasides D, Fountzilas G.
    PLoS One; 2015 Jan 15; 10(10):e0140293. PubMed ID: 26452060
    [Abstract] [Full Text] [Related]

  • 19. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ, Brauer H, Horn S, Yigit G, Haider MT, Pogenberg V, Schumacher U, Pantel K, Jücker M.
    Cell Signal; 2024 Sep 15; 121():111270. PubMed ID: 38909932
    [Abstract] [Full Text] [Related]

  • 20. Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.
    Kandula M, Chennaboina KK, Ys AR, Raju S.
    Asian Pac J Cancer Prev; 2013 Sep 15; 14(9):5067-72. PubMed ID: 24175777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.